DOCSLIB.ORG

Immunogenicity of Cell Death Driven by Immune Effectors

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Immunogenicity of Cell Death Driven by Immune Effectors Open access Commentary J Immunother Cancer: first published as 10.1136/jitc-2020-000802 on 5 April 2020. Downloaded from Immunogenicity of cell death driven by immune effectors Lorenzo Galluzzi,1,2,3,4,5 Giulia Petroni,1 Guido Kroemer5,6,7,8,9,10 To cite: Galluzzi L, Petroni G, ABSTRACT immunogenic cell death (ICD)4 was missing. Kroemer G. Immunogenicity Whether cell death caused by T lymphocytes and natural Novel findings from the laboratories of Dr of cell death driven by killer (NK) cells would be immunogenic per se has been a Melero and Dr Pardo elegantly resolve this immune effectors. Journal for matter of intense debate. Two back- to-back papers from ImmunoTherapy of Cancer conundrum as they demonstrate that cancer the Melero’s and Pardo’s groups have now resolved this 2020;8:e000802. doi:10.1136/ cells succumbing to immune effectors display conundrum, demonstrating that T and NK cell–mediated jitc-2020-000802 sufficient antigenicity and adjuvanticity to cytotoxicity represents indeed a bona fide variant of initiate adaptive immune responses in immu- LG and GK are joint senior immunogenic cell death. 5 6 authors. nocompetent hosts. By harnessing both parental and genet- Accepted 21 March 2020 ically modified mouse cancer cell lines Preclinical and clinical data accumulating including MC38 colorectal carcinoma cells over the past two decades demonstrate and EL4 lymphoma cells, these authors that—irrespective of treatment modality— elegantly demonstrated that cancer cells the success of cancer therapy most often succumbing to antigen- specific CTLs or NK relies on the activation of a robust immune cells in vitro display surrogate markers of ICD response with systemic outreach.1 A key role such as the exposure of calreticulin (CALR) in this context is played by so- called “epitope on the surface of the plasma membrane and spreading,” that is, the diversification of the release of high mobility group Box 1 an adaptive immune response that initially (HGMB1) into the extracellular space. When targets only one or a few antigenic determi- inoculated in immunocompetent syngeneic nants but ultimately involves multiple T- cell mice as a prophylactic vaccine, such dying clones specific for a variety of epitopes. cells conferred robust protection against a Indeed, the vast majority of solid neoplasms subsequent challenge with living cells of the display an elevated antigenic heterogeneity same parental type, as well as with different http://jitc.bmj.com/ that generally compromises the efficacy of cells genetically engineered to express a immune responses targeting a single antigen, shared antigen. In particular, ovalbumin as demonstrated by a plethora of therapeutic (OVA)- expressing MC38 exogenously pulsed vaccines ultimately failing clinical testing.2 with an immunogenic epitope from premel- From an immunological perspective, epitope anosome protein (PMEL, best known as spreading obligatorily relies on several steps: gp100) and then exposed to gp100- specific on September 23, 2021 by guest. Protected copyright. (1) the release of novel antigenic material CTLs could successfully vaccinate C57BL/6 by cancer cells succumbing to the initial mice against a challenge with OVA- expressing immune response; (2) the uptake of such EL4 cells (commonly known as EG7 cells). material by antigen-presenting cells (APCs) This elegant experimental design demon- and their migration to secondary lymphoid strated epitope spreading in vivo.5 6 organs or tertiary lymphoid structures; and In line with an expanding literature on © Author(s) (or their 7 employer(s)) 2020. Re- use (3) the cross-priming of naive T-cell clones in the molecular determinants of ICD, mouse permitted under CC BY-NC. No the context of sufficient co- stimulatory signals cancer cells killed by CTLs or NK cells failed commercial re- use. See rights for them to acquire effector functions.3 Thus, to protect syngeneic immunocompetent and permissions. Published by the death of cancer cells attacked by CD8+ hosts from a challenge with antigenically BMJ. cytotoxic T lymphocytes (CTLs) must be able, compatible cells on the antibody-mediated For numbered affiliations see + end of article. at least in some instances, to re- initiate the depletion of CD8 CTLs as well as on the cancer- immunity cycle and ultimately lead whole- body knockout of Prf1, which encode Correspondence to to the generation of additional CTLs with the central cytotoxic molecule perforin Dr Lorenzo Galluzzi; broadened specificity.3 Until now, however, 1. The prophylactic effect of cancer cells deadoc80@ gmail. com formal demonstration that cellular cytotox- succumbing to CTLs or NK cells was also lost Guido Kroemer; icity as mediated by CTLs and natural killer in mice lacking the HMGB1 receptor Toll- kroemer@ orange. fr (NK) cells constitutes a bona fide variant of like receptor 4 (TLR4), as well as in mice Galluzzi L, et al. J Immunother Cancer 2020;8:e000802. doi:10.1136/jitc-2020-000802 1 Open access J Immunother Cancer: first published as 10.1136/jitc-2020-000802 on 5 April 2020. Downloaded from this notion, BCL-X L overexpression had little effects on sensitivity to death by immune effectors, which correlated with a minimal influence on vaccination efficacy.5 Thus, the impact of CASP3 on the efficacy of vaccination with cancer cells succumbing to CTLs and NK cells appears to be largely limited to its ability to precipitate cell death in this setting, which does not apply to ICD driven by other stimuli including radiation.8–10 Early work from the late Jurg Tschopp and colleagues demonstrated that the lytic granules of CTLs contain high levels of CALR, which was interpreted as a safeguard mechanism to prevent PRF1 activation by Ca2+ ions prior to granule exocytosis, largely relying on the ability of CALR to chelate Ca2+.11 Thus, it is possible that (at least part of) the CALR molecules detected on the surface of cancer cells attacked by CTLs (or NK cells) may be provided in trans by the latter (rather than in cis by the former) along with PRF1 and the other cytotoxic mole- Figure 1 Cellular cytotoxicity as a potential source of cules contained in lytic granules. Vaccination experiments adjuvanticity in trans. In the context of chemotherapy- with Calr−/− cancer cells are urgently awaited to clarify induced and radiation therapy–induced immunogenic the relative contribution of endogenous vs exogenous cell death (ICD), the phagocytosis-stimulatory molecule calreticulin (CALR) is exposed on the surface of dying CALR to the immunogenic potential of cellular cytotox- cells as a consequence of anterograde transport from icity. Such a mechanistic exploration may be particularly the endoplasmic reticulum (ER) to the plasma membrane important for the development of next-generation CAR T via the Golgi apparatus (GA) (A). When ICD is initiated by cells endowed with superior cytotoxic functions and also cytotoxic T lymphocytes (CTLs) or natural killer (NK) cells, with the capacity to transfer adjuvanticity to their target, however, surface-exposed CALR may be provided by de facto favoring epitope spreading (figure 1). Irrespective immune effectors (at least in part). This mechanism could be of this and other unresolved conundrums, the current harnessed to improve the therapeutic efficacy of CAR T cells findings from Dr Melero’s and Dr Pardo’s groups shed by maximizing their ability to deliver adjuvant- like signals to their targets, ultimately resulting in superior epitope spreading new light onto the contribution of ICD to therapeutically (B). PRF1, perforin 1. relevant immune responses in the context of the cancer- immunity cycle. that are deficient in cross-priming as a consequence of Author affiliations http://jitc.bmj.com/ stimulator of interferon response cGAMP interactor 1Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, 1 (Sting1) or basic leucine zipper transcription factor, USA 5 6 2Sandra and Edward Meyer Cancer Center, New York, NY, United States ATF- like 3 (Batf3) deletion. Conversely, the results 3 from Pardo and colleagues appear to challenge the Caryl and Israel Englander Institute for Precision Medicine, New York, NY, United States current literature in proposing that caspase 3 (CASP3), 4Department of Dermatology, Yale School of Medicine, New Haven, CT, United States a key regulator of apoptosis with multipronged immu- 5Université de Paris, Paris, France on September 23, 2021 by guest. Protected copyright. nosuppressive effects including the ability to shut down 6Equipe labellisée par la Ligue contre le cancer, INSERM U1138, Centre de type I interferon production by STING1,8–10 is required Recherche des Cordeliers, Paris, France 7 for the immunogenicity of cancer cells succumbing to Metabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer 5 Institute, Villejuif, France immune effectors. This interpretation was based on the 8Pôle de Biologie, Hôpital Européen Georges Pompidou, AP- HP, Paris, France ability of chemical pan-caspase inhibitor (Q- VD- OPh) 9Suzhou Institute for Systems Medicine, Chinese Academy of Sciences, Suzhou, and a dominant-negative variant of CASP3, but not the China overexpression of BCL2- like 1 (BCL2L1, a potent anti- 10Department of Women's and Children's Health, Karolinska University Hospital, Stockholm, Sweden apoptotic molecule best known as BCL- XL), to reduce (to some degree) immunological protection conferred Contributors LG conceived the article and wrote the first version of the manuscript by cancer cells dying on attack by antigen-specific
Load more

Recommended publications
  • Guideline on Immunogenicity Assessment of Biotechnology-Derived Therapeutic Proteins
    European Medicines Agency London, 13 December 2007 Doc. Ref. EMEA/CHMP/BMWP/14327/2006 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON IMMUNOGENICITY ASSESSMENT OF BIOTECHNOLOGY-DERIVED THERAPEUTIC PROTEINS DRAFT AGREED BY BMWP July 2006 ADOPTION BY CHMP FOR RELEASE FOR CONSULTATION January 2007 END OF CONSULTATION (DEADLINE FOR COMMENTS) July 2007 AGREED BY BMWP October 2007 ADOPTION BY CHMP December 2007 DATE FOR COMING INTO EFFECT April 2008 KEYWORDS Immunogenicity, unwanted immune response, biotechnology derived proteins, immunogenicity risk factors, assays, clinical efficacy and safety, risk management 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 86 13 E-mail: [email protected] http://www.emea.europa.eu ©EMEA 2007 Reproduction and/or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged GUIDELINE ON IMMUNOGENICITY ASSESSMENT OF BIOTECHNOLOGY-DERIVED THERAPEUTIC PROTEINS TABLE OF CONTENTS EXECUTIVE SUMMARY................................................................................................................... 3 1. INTRODUCTION......................................................................................................................... 3 2. SCOPE............................................................................................................................................ 4 3. LEGAL BASIS .............................................................................................................................
    [Show full text]
  • Risk Assessment and Mitigation Strategies for Immune Responses to Therapeutic Proteins: the FDA Perspective
    Risk Assessment and Mitigation Strategies for Immune Responses to Therapeutic Proteins: the FDA Perspective Amy S. Rosenberg, M.D. Supervisory Medical Officer, Office of Biotechnology Products CDER, FDA Risk is a Specific Knowledge Set Encompassing Both Consequences and Probabilities (modified from Stirling and Gee 2002) Knowledge about Consequences Knowledge about likelihoods Consequences Consequences well-defined poorly-defined Some basis Ambiguity Risk (I) for (III) probabilities Incertitude No basis for Uncertainty Ignorance probabilities (II) (IV) “Guidance for Industry Immunogenicity Assessment for Therapeutic Protein Products” U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) August 2014 Clinical/Medical 3 Immunogenicity Risk Assessment: Consequences for Safety • Fatality/Severe Morbidity – Anaphylaxis: clinical definition, does not imply mechanism • Proteins of non-human origin, eg, aprotinin, asparaginase • Replacement human proteins in knock out phenotype: eg, Factor IX in hemophilia B – Cross reactive neutralization of endogenous factor or receptor homolog with unique function resulting in deficiency syndrome or cytokine release syndrome – Immune complex disease and delayed hypersensitivity • Serum sickness; nephropathy • Most often seen when high doses of therapeutic proteins are administered in setting of a sustained high titered antibody response Immunogenicity Risk Assessment Consequences for Efficacy
    [Show full text]
  • Nanosecond-Pulsed DBD Plasma-Generated Reactive Oxygen Species Trigger Immunogenic Cell Death in A549 Lung Carcinoma Cells Through Intracellular Oxidative Stress
    International Journal of Molecular Sciences Article Nanosecond-Pulsed DBD Plasma-Generated Reactive Oxygen Species Trigger Immunogenic Cell Death in A549 Lung Carcinoma Cells through Intracellular Oxidative Stress Abraham Lin 1, Billy Truong 1, Sohil Patel 1, Nagendra Kaushik 2, Eun Ha Choi 2, Gregory Fridman 1, Alexander Fridman 1 and Vandana Miller 1,* 1 C. & J. Nyheim Plasma Institute, Drexel University, Philadelphia, PA 19104, USA; [email protected] (A.L.); [email protected] (B.T.); [email protected] (S.P.); [email protected] (G.F.); [email protected] (A.F.) 2 Plasma Bioscience Research Center, Kwangwoon University, Seoul 139791, Korea; [email protected] (N.K.); [email protected] (E.H.C.) * Correspondence: [email protected]; Tel.: +1-215-571-4074 Academic Editor: Hsueh-Wei Chang Received: 1 March 2017; Accepted: 28 April 2017; Published: 3 May 2017 Abstract: A novel application for non-thermal plasma is the induction of immunogenic cancer cell death for cancer immunotherapy. Cells undergoing immunogenic death emit danger signals which facilitate anti-tumor immune responses. Although pathways leading to immunogenic cell death are not fully understood; oxidative stress is considered to be part of the underlying mechanism. Here; we studied the interaction between dielectric barrier discharge plasma and cancer cells for oxidative stress-mediated immunogenic cell death. We assessed changes to the intracellular oxidative environment after plasma treatment and correlated it to emission of two danger signals: surface-exposed calreticulin and secreted adenosine triphosphate. Plasma-generated reactive oxygen and charged species were recognized as the major effectors of immunogenic cell death. Chemical attenuators of intracellular reactive oxygen species successfully abrogated oxidative stress following plasma treatment and modulated the emission of surface-exposed calreticulin.
    [Show full text]
  • Measuring the Immunogenicity of Allogeneic Adult Mesenchymal Stem Cells Alix K
    Berglund et al. Stem Cell Research & Therapy (2017) 8:288 DOI 10.1186/s13287-017-0742-8 REVIEW Open Access Immunoprivileged no more: measuring the immunogenicity of allogeneic adult mesenchymal stem cells Alix K. Berglund1*, Lisa A. Fortier2, Douglas F. Antczak3 and Lauren V. Schnabel1* Abstract Background: Autologous and allogeneic adult mesenchymal stem/stromal cells (MSCs) are increasingly being investigated for treating a wide range of clinical diseases. Allogeneic MSCs are especially attractive due to their potential to provide immediate care at the time of tissue injury or disease diagnosis. The prevailing dogma has been that allogeneic MSCs are immune privileged, but there have been very few studies that control for matched or mismatched major histocompatibility complex (MHC) molecule expression and that examine immunogenicity in vivo. Studies that control for MHC expression have reported both cell-mediated and humoral immune responses to MHC-mismatched MSCs. The clinical implications of immune responses to MHC-mismatched MSCs are still unknown. Pre-clinical and clinical studies that document the MHC haplotype of donors and recipients and measure immune responses following MSC treatment are necessary to answer this critical question. Conclusions: This review details what is currently known about the immunogenicity of allogeneic MSCs and suggests contemporary assays that could be utilized in future studies to appropriately identify and measure immune responses to MHC-mismatched MSCs. Keywords: Mesenchymal stem cell, Allogeneic, Immunogenicity, Major histocompatibility complex, Mixed leukocyte reaction, Cytotoxicity, ELISPOT, Microcytotoxicity Background in vivo [9], questioning the relevance of differentiation Mesenchymal stem cells (MSCs) are currently defined as to the therapeutic properties of MSCs when injected in a plastic-adherent cells with a fibroblast-like morphology naive state.
    [Show full text]
  • Killing Cancer Cells, Twice with One Shot
    Cell Death and Differentiation (2014) 21, 1–2 & 2014 Macmillan Publishers Limited All rights reserved 1350-9047/14 www.nature.com/cdd Editorial Killing cancer cells, twice with one shot ME Bianchi*,1 Cell Death and Differentiation (2014) 21, 1–2; doi:10.1038/cdd.2013.147 I can still remember lecturing that chemotherapy and radio- shows that transglutaminase (TG) 2, a protein with several therapy are effective because they kill cancer cells. That was complex activities, can prevent calreticulin exposure on the simple enough, and when I wanted to make it a bit more cell surface, and therefore TG2-overexpressing cancer cells complex, I ventured into explaining how they mainly killed can escape activation of the immune system.9 cancer cells because they divided much more than other cells, Curiously, calreticulin is also surface exposed by spermato- and how the killing involved apoptosis. Things have moved on zoa, both in mammals and nematodes, to facilitate fertiliza- quite a bit since then. Evidence accumulated in the past few tion. Following the phylogenetic trail to its widest extent, years indicates that some anti-cancer drugs do not kill cancer Sukkurwala et al.10 show that yeast calreticulin, CNE1 protein, cells, but merely push them into senescence, some do kill is surface exposed following ER stress, and facilitates yeast cells but not via apoptosis, and some do kill cells via apoptosis mating too.10 The binding of yeast pheromone a-factor to its G but that is not the main ingredient in their efficacy. protein-coupled receptor (GPCR) induces CNE1 surface The main theme of this issue is that dying cancer cells presentation.
    [Show full text]
  • Stress-Induced Inflammation Evoked by Immunogenic Cell Death Is
    www.nature.com/cdd ARTICLE OPEN Stress-induced inflammation evoked by immunogenic cell death is blunted by the IRE1α kinase inhibitor KIRA6 through HSP60 targeting Nicole Rufo1,2, Dimitris Korovesis3,Sofie Van Eygen1,2, Rita Derua4, Abhishek D. Garg 1, Francesca Finotello5, Monica Vara-Perez1,2, ž 6,7 2,8 9 7,10 11 6 Jan Ro anc , Michael Dewaele , Peter A. de Witte , Leonidas G. Alexopoulos✉ , Sophie Janssens , Lasse Sinkkonen , Thomas Sauter6, Steven H. L. Verhelst 3,12 and Patrizia Agostinis 1,2 © The Author(s) 2021 Mounting evidence indicates that immunogenic therapies engaging the unfolded protein response (UPR) following endoplasmic reticulum (ER) stress favor proficient cancer cell-immune interactions, by stimulating the release of immunomodulatory/ proinflammatory factors by stressed or dying cancer cells. UPR-driven transcription of proinflammatory cytokines/chemokines exert beneficial or detrimental effects on tumor growth and antitumor immunity, but the cell-autonomous machinery governing the cancer cell inflammatory output in response to immunogenic therapies remains poorly defined. Here, we profiled the transcriptome of cancer cells responding to immunogenic or weakly immunogenic treatments. Bioinformatics-driven pathway analysis indicated that immunogenic treatments instigated a NF-κB/AP-1-inflammatory stress response, which dissociated from both cell death and UPR. This stress-induced inflammation was specifically abolished by the IRE1α-kinase inhibitor KIRA6. Supernatants from immunogenic chemotherapy and KIRA6 co-treated cancer cells were deprived of proinflammatory/chemoattractant factors and failed to mobilize neutrophils and induce dendritic cell maturation. Furthermore, KIRA6 significantly reduced the in vivo vaccination potential of dying cancer cells responding to immunogenic chemotherapy. Mechanistically, we found that the anti-inflammatory effect of KIRA6 was still effective in IRE1α-deficient cells, indicating a hitherto unknown off-target effector of this IRE1α-kinase inhibitor.
    [Show full text]
  • Size, Affinity, and Immunogenicity Peptide-Binding Repertoires Of
    HLA Class I Alleles Are Associated with Peptide-Binding Repertoires of Different Size, Affinity, and Immunogenicity This information is current as Sinu Paul, Daniela Weiskopf, Michael A. Angelo, John of September 29, 2021. Sidney, Bjoern Peters and Alessandro Sette J Immunol 2013; 191:5831-5839; Prepublished online 4 November 2013; doi: 10.4049/jimmunol.1302101 http://www.jimmunol.org/content/191/12/5831 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2013/11/05/jimmunol.130210 Material 1.DC1 http://www.jimmunol.org/ References This article cites 51 articles, 12 of which you can access for free at: http://www.jimmunol.org/content/191/12/5831.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision by guest on September 29, 2021 • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2013 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology HLA Class I Alleles Are Associated with Peptide-Binding Repertoires of Different Size, Affinity, and Immunogenicity Sinu Paul,1 Daniela Weiskopf,1 Michael A.
    [Show full text]
  • Pathogen Response-Like Recruitment and Activation of Neutrophils by Sterile Immunogenic Dying Cells Drives Neutrophil-Mediated Residual Cell Killing
    Cell Death and Differentiation (2017) 24, 832–843 & 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved 1350-9047/17 www.nature.com/cdd Pathogen response-like recruitment and activation of neutrophils by sterile immunogenic dying cells drives neutrophil-mediated residual cell killing Abhishek D Garg*,1,2, Lien Vandenberk3, Shentong Fang4, Tekele Fasche4, Sofie Van Eygen1, Jan Maes5, Matthias Van Woensel6,7, Carolien Koks3, Niels Vanthillo5, Norbert Graf8, Peter de Witte5, Stefaan Van Gool9, Petri Salven4 and Patrizia Agostinis*,1 Innate immune sensing of dying cells is modulated by several signals. Inflammatory chemokines-guided early recruitment, and pathogen-associated molecular patterns-triggered activation, of major anti-pathogenic innate immune cells like neutrophils distinguishes pathogen-infected stressed/dying cells from sterile dying cells. However, whether certain sterile dying cells stimulate innate immunity by partially mimicking pathogen response-like recruitment/activation of neutrophils remains poorly understood. We reveal that sterile immunogenic dying cancer cells trigger (a cell autonomous) pathogen response-like chemokine (PARC) signature, hallmarked by co-release of CXCL1, CCL2 and CXCL10 (similar to cells infected with bacteria or viruses). This PARC signature recruits preferentially neutrophils as first innate immune responders in vivo (in a cross-species, evolutionarily conserved manner; in mice and zebrafish). Furthermore, key danger signals emanating from these dying cells, that is, surface calreticulin, ATP and nucleic acids stimulate phagocytosis, purinergic receptors and toll-like receptors (TLR) i.e. TLR7/8/9-MyD88 signaling on neutrophil level, respectively. Engagement of purinergic receptors and TLR7/8/9-MyD88 signaling evokes neutrophil activation, which culminates into H2O2 and NO-driven respiratory burst-mediated killing of viable residual cancer cells.
    [Show full text]
  • Α-TEA's Tumor Toxicity May Be Attributed to Its Capability of Inducing Oxidative Damage in the Endoplasmic Reticulum
    Portland State University PDXScholar University Honors Theses University Honors College 2015 α-TEA's Tumor Toxicity may be Attributed to its Capability of Inducing Oxidative Damage in the Endoplasmic Reticulum Diego Mathias Barragan Echenique Portland State University Follow this and additional works at: https://pdxscholar.library.pdx.edu/honorstheses Let us know how access to this document benefits ou.y Recommended Citation Barragan Echenique, Diego Mathias, "α-TEA's Tumor Toxicity may be Attributed to its Capability of Inducing Oxidative Damage in the Endoplasmic Reticulum" (2015). University Honors Theses. Paper 124. https://doi.org/10.15760/honors.172 This Thesis is brought to you for free and open access. It has been accepted for inclusion in University Honors Theses by an authorized administrator of PDXScholar. Please contact us if we can make this document more accessible: [email protected]. α-TEA’s Tumor Toxicity may be Attributed to its Capability of Inducing Oxidative Damage in the Endoplasmic Reticulum by Diego Mathias Barragan Echenique An undergraduate honors thesis submitted in partial fulfillment of the requirements for the degree of Bachelor of Science in University Honors and Biology Thesis Adviser William L. Redmond, PhD Portland State University 2015 Abstract α-tocopherol ether linked acetic acid (α-TEA) is a Vitamin E derivative with antineoplastic and anti-metastatic properties, tumor specificity, and immunogenic characteristics. The compound is structurally similar to vitamin E, however a key difference is that it doesn’t retain any antioxidant properties. Interestingly, orally administered α-TEA appears to stimulate anti-tumor immunity, which, along with its anti-metastatic and antineoplastic properties, makes the molecule’s mechanism of action worth investigating.
    [Show full text]
  • Reactive Oxygen Species and Antitumor Immunity—From Surveillance to Evasion
    cancers Review Reactive Oxygen Species and Antitumor Immunity—From Surveillance to Evasion Andromachi Kotsafti 1 , Marco Scarpa 2 , Ignazio Castagliuolo 3 and Melania Scarpa 1,* 1 Laboratory of Advanced Translational Research, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy; [email protected] 2 General Surgery Unit, Azienda Ospedaliera di Padova, 35128 Padua, Italy; [email protected] 3 Department of Molecular Medicine DMM, University of Padua, 35121 Padua, Italy; [email protected] * Correspondence: [email protected] Received: 8 June 2020; Accepted: 28 June 2020; Published: 1 July 2020 Abstract: The immune system is a crucial regulator of tumor biology with the capacity to support or inhibit cancer development, growth, invasion and metastasis. Emerging evidence show that reactive oxygen species (ROS) are not only mediators of oxidative stress but also players of immune regulation in tumor development. This review intends to discuss the mechanism by which ROS can affect the anti-tumor immune response, with particular emphasis on their role on cancer antigenicity, immunogenicity and shaping of the tumor immune microenvironment. Given the complex role that ROS play in the dynamics of cancer-immune cell interaction, further investigation is needed for the development of effective strategies combining ROS manipulation and immunotherapies for cancer treatment. Keywords: reactive oxygen species; oxidative stress; immunity; inflammation; cancer 1. Introduction Reactive oxygen species (ROS) are defined as chemically reactive derivatives of oxygen that elicits both harmful and beneficial effects in cells depending on their concentration. Oxidative stress occurs when ROS production overcomes the scavenging potential of cells or when the antioxidant response is severely impaired; as a consequence nonradical and free radical ROS such as hydrogen peroxide (H2O2), the superoxide radical (O2•) or the hydroxyl radical (OH•) accumulate [1].
    [Show full text]
  • Immunogenicity Assessment of Therapeutic Proteins
    European Medicines Agency London, 24 January 2007 Doc. Ref. EMEA/CHMP/BMWP/14327/2006 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT GUIDELINE ON IMMUNOGENICITY ASSESSMENT OF BIOTECHNOLOGY-DERIVED THERAPEUTIC PROTEINS DRAFT AGREED BY BMWP July 2006 ADOPTION BY CHMP FOR RELEASE FOR CONSULTATION 24 January 2007 END OF CONSULTATION (DEADLINE FOR COMMENTS) 31 July 2007 Comments should be provided electronically in word format using this template to: [email protected] KEYWORDS Immunogenicity, biotechnology derived proteins, antigenicity risk factors, assays, clinical efficacy 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 86 13 E-mail: [email protected] http://www.emea.europa.eu ©EMEA 2007 Reproduction and/or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged GUIDELINE ON IMMUNOGENICITY ASSESSMENT OF BIOTECHNOLOGY-DERIVED THERAPEUTIC PROTEINS TABLE OF CONTENTS EXECUTIVE SUMMARY................................................................................................................... 3 1. INTRODUCTION......................................................................................................................... 3 2. SCOPE............................................................................................................................................ 3 3. LEGAL BASIS .............................................................................................................................
    [Show full text]
  • Immune Escape Mechanisms As a Guide for Cancer Immunotherapy Gregory L
    Published OnlineFirst December 12, 2014; DOI: 10.1158/1078-0432.CCR-14-1860 Perspectives Clinical Cancer Research Immune Escape Mechanisms as a Guide for Cancer Immunotherapy Gregory L. Beatty and Whitney L. Gladney Abstract Immunotherapy has demonstrated impressive outcomes for exploited by cancer and present strategies for applying this some patients with cancer. However, selecting patients who are knowledge to improving the efficacy of cancer immunotherapy. most likely to respond to immunotherapy remains a clinical Clin Cancer Res; 21(4); 1–6. Ó2014 AACR. challenge. Here, we discuss immune escape mechanisms Introduction fore, promote tumor outgrowth. In this process termed "cancer immunoediting," cancer clones evolve to avoid immune-medi- The immune system is a critical regulator of tumor biology with ated elimination by leukocytes that have antitumor properties the capacity to support or inhibit tumor development, growth, (6). However, some tumors may also escape elimination by invasion, and metastasis. Strategies designed to harness the recruiting immunosuppressive leukocytes, which orchestrate a immune system are the focus of several recent promising thera- microenvironment that spoils the productivity of an antitumor peutic approaches for patients with cancer. For example, adoptive immune response (7). Thus, although the immune system can be T-cell therapy has produced impressive remissions in patients harnessed, in some cases, for its antitumor potential, clinically with advanced malignancies (1). In addition, therapeutic mono- relevant tumors appear to be marked by an immune system that clonal antibodies designed to disrupt inhibitory signals received actively selects for poorly immunogenic tumor clones and/or by T cells through the cytotoxic T-lymphocyte–associated antigen establishes a microenvironment that suppresses productive anti- 4 (CTLA-4; also known as CD152) and programmed cell death-1 tumor immunity (Fig.
    [Show full text]